Efficacy and safety of aducanumab, lecanemab, and donanemab in Alzheimer's disease: A meta-analysis of randomized controlled trials. (PubMed, J Alzheimers Dis) - Sep 29, 2026 - "Brain-volume loss, ventricular enlargement, and treatment-related deaths were narratively identified but not pooled.ConclusionsAducanumab, lecanemab, and donanemab showed statistically significant but small slowing of decline that may not reach patient-perceptible clinical meaningfulness. Increased ARIA risk and additional safety signals support cautious selection, imaging surveillance, and individualized risk-benefit discussions."
Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Dementia • APOE
|
|
Adriana Rodríguez; Ahmed Koriesh; Deepak Kalra; Haroon Shabbir; Maheen Shaharyar; Mansour Afshani; Muaz Ali; Sindu Mukesh
|